Medesis Pharma S.A. (ALMDP.PA)
EUR 0.34
(-2.86%)
EUR 0.34
(-2.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.42 Million EUR | 116.12% |
| 2022 | 2.97 Million EUR | 10.94% |
| 2021 | 2.68 Million EUR | -8.23% |
| 2020 | 2.92 Million EUR | -6.75% |
| 2019 | 3.13 Million EUR | 25.28% |
| 2018 | 2.5 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 4.31 Million EUR | -0.0% |
| 2023 FY | 6.42 Million EUR | 116.12% |
| 2023 Q4 | 6.42 Million EUR | 0.0% |
| 2023 Q3 | 6.42 Million EUR | 48.78% |
| 2023 Q1 | 4.31 Million EUR | 45.26% |
| 2022 Q4 | 2.97 Million EUR | 0.0% |
| 2022 Q3 | 2.97 Million EUR | 3.1% |
| 2022 FY | 2.97 Million EUR | 10.94% |
| 2022 Q2 | 2.88 Million EUR | 0.0% |
| 2022 Q1 | 2.88 Million EUR | 7.61% |
| 2021 Q3 | 2.07 Million EUR | -19.76% |
| 2021 Q2 | 2.58 Million EUR | 58.95% |
| 2021 Q1 | 1.62 Million EUR | -44.31% |
| 2021 Q4 | 2.68 Million EUR | 29.19% |
| 2021 FY | 2.68 Million EUR | -8.23% |
| 2020 Q2 | 3.36 Million EUR | 0.0% |
| 2020 FY | 2.92 Million EUR | -6.75% |
| 2020 Q4 | 2.92 Million EUR | 24.83% |
| 2020 Q3 | 2.33 Million EUR | -30.49% |
| 2019 FY | 3.13 Million EUR | 25.28% |
| 2018 FY | 2.5 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | 7.029% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 95.096% |
| Adocia SA | 31.87 Million EUR | 79.836% |
| Aelis Farma SA | 13.08 Million EUR | 50.87% |
| Biophytis S.A. | 15.84 Million EUR | 59.454% |
| Advicenne S.A. | 24.37 Million EUR | 73.638% |
| genOway Société anonyme | 14.45 Million EUR | 55.557% |
| IntegraGen SA | 5.97 Million EUR | -7.465% |
| Neovacs S.A. | 3.71 Million EUR | -73.113% |
| NFL Biosciences SA | 3.62 Million EUR | -77.485% |
| Plant Advanced Technologies SA | 6.78 Million EUR | 5.251% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -94.138% |
| Sensorion SA | 13.22 Million EUR | 51.417% |
| Theranexus Société Anonyme | 5.01 Million EUR | -28.109% |
| TME Pharma N.V. | 2.78 Million EUR | -130.743% |
| Valbiotis SA | 13.7 Million EUR | 53.121% |
| TheraVet SA | 1.48 Million EUR | -332.742% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 68.604% |
| argenx SE | 402.79 Million EUR | 98.405% |
| BioSenic S.A. | 32.26 Million EUR | 80.082% |
| Celyad Oncology SA | 9.97 Million EUR | 35.596% |
| DBV Technologies S.A. | 38.74 Million USD | 83.414% |
| Galapagos NV | 1.56 Billion EUR | 99.589% |
| Genfit S.A. | 105.92 Million EUR | 93.933% |
| GeNeuro SA | 20.13 Million EUR | 68.092% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | 25.381% |
| Innate Pharma S.A. | 132.29 Million EUR | 95.142% |
| Inventiva S.A. | 101.59 Million EUR | 93.675% |
| MaaT Pharma SA | 22.46 Million EUR | 71.395% |
| MedinCell S.A. | 77.77 Million EUR | 91.737% |
| Nanobiotix S.A. | 95.74 Million EUR | 93.288% |
| Onward Medical N.V. | 25.69 Million EUR | 74.993% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 74.424% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 89.123% |
| Oxurion NV | 19.73 Million EUR | 67.439% |
| Pharming Group N.V. | 228.28 Million EUR | 97.185% |
| Poxel S.A. | 53.9 Million EUR | 88.078% |
| GenSight Biologics S.A. | 34.72 Million EUR | 81.495% |
| Transgene SA | 26.51 Million EUR | 75.766% |
| Financière de Tubize SA | 123.65 Million EUR | 94.803% |
| UCB SA | 6.56 Billion EUR | 99.902% |
| Valneva SE | 341.14 Million EUR | 98.116% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -41.328% |